Successful treatment of chronic hepatitis C virus infection in severely opioid-dependent patients under heroin maintenance

Drug and Alcohol Dependence

Volumn 109, Issue 1-3, 2010, Pages 248-251

  Schulte, Bernd ^a,b   Schütt, Sabine ^c   Brack, Jochen ^d   Isernhagen, Konrad ^e   Deibler, Peter ^f   Dilg, Christoph ^g   Verthein, Uwe ^a   Haasen, Christian ^a   Reimer, Jens ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Institute for Therapy Research   (Germany)

^c Asklepios Hospital North   (Germany)

^d Clinic for Neurology and Psychiatry Rahlstedt   (Germany)

^e Clinic for General Medicine   (Germany)

^f CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^g UNIVERSITY OF BONN   (Germany)

Author keywords

Antiviral treatment; Hepatitis C; Heroin maintenance; Injection drug use

Indexed keywords

DIAMORPHINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ANEMIA; ARTICLE; COGNITIVE DEFECT; DELIRIUM; DEPRESSION; DRUG RESPONSE; DRUG WITHDRAWAL; DRY SKIN; FEMALE; FLU LIKE SYNDROME; GENOTYPE; HAIR LOSS; HEPATITIS C; HUMAN; LEUKOPENIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SUICIDAL IDEATION;

ADULT; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; GERMANY; HEALTH STATUS; HEPACIVIRUS; HEPATITIS C; HEROIN; HEROIN DEPENDENCE; HUMANS; INTERFERONS; MALE; MENTAL HEALTH; MIDDLE AGED; NARCOTICS; RIBAVIRIN; SUBSTANCE ABUSE TREATMENT CENTERS; SUBSTANCE ABUSE, INTRAVENOUS; VIRAL LOAD; YOUNG ADULT;

HEPATITIS C VIRUS;

EID: 77953024803     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2010.01.009     Document Type: Article

References (22)

1. Darke S., Hall W., Wodak A., Heather N., Ward J. Development and validation of a multi-dimensional instrument for assessing outcome of treatment among opiate users: the Opiate Treatment Index. Br. J. Addict. 1992, 87:733-742.
2. Darke S., Ward J., Zador D., Swift G. A scale for estimating the health status of opioid users. Br. J. Addict. 1991, 86:1317-1322.
3. Derogatis L.R. SCL-90-R, Administration, Scoring & Procedures Manual for the R(evised) Version 1997, Johns Hopkins University School of Medicine, Baltimore.
4. Edlin B.R., Seal K.H., Lorvick J., Kral A.H., Ciccarone D.H., Moore L.D., Lo B. Is it justifiable to withhold treatment for hepatitis C from illicit drug users?. N. Engl. J. Med. 2001, 345:211-215.
5. Fried R., Monnat M., Seidenberg A., Oppliger R., Schmid P., Herold M., Isler M., Broers B., Kölliker C., Schönbucher P., Frei M., Huber M. Swiss multicenter study evaluating the efficacy, feasibility and safety of peginterferon-alfa-2a and ribavirin in patients with chronic hepatitis C in official opiate substitution programs. Digestion 2008, 78:123-130.
6. Grebely J., deVlaming S., Duncan F., Viljoen M., Conway B. Current approaches to HCV infection in current and former injection drug users. J. Addict. Dis. 2008, 27:25-35.
7. Grebely J., Raffa J.D., Meagher C., Duncan F., Genoway K.A., Khara M., McLean M., Mead A., Viljoen M., deVlaming S., Fraser C., Conway B. Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users. J. Gastroenterol. Hepatol. 2007, 22:1519-1525.
8. Haasen C., Verthein U., Degkwitz P., Berger J., Krausz M., Naber D. Heroin-assisted treatment for opioid dependence: randomised controlled trial. Br. J. Psychiatry 2007, 191:55-62.
9. Hellard M., Sacks-Davis R., Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin. Infect. Dis. 2009, 49:561-573.
10. Krook A., Stokka D., Heger B., Nygaard E. Hepatitis C treatment of opioid dependents receiving maintenance treatment: results of a Norwegian pilot study. Eur. Addict. Res. 2007, 13:216-221.
11. Lumbreras B., Jarrín I., del Amo J., Pérez-Hoyos S., Muga R., Hera M.G., Ferreros I., Sanvisens A., Hurtado I., Hernández-Aguado I. Impact of hepatitis C infection on long-term mortality of injection drug users from 1990 to 2002: differences before and after HAART. AIDS 2006, 20:111-116.
12. Manns M., McHutchison J., Gordon S., Rustgi V.K., Shiffman M., Reindollar R., Goodman Z.D., Koury K., Ling M., Albrecht J.K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
13. McHutchison J.G., Lawitz E.J., Shiffman M.L., Muir A.J., Galler G.W., McCone J., Nyberg L.M., Lee W.M., Ghalib R.H., Schiff E.R., Galati J.S., Bacon B.R., Davis M.N., Mukhopadhyay P., Koury K., Noviello S., Pedicone L.D., Brass C.A., Albrecht J.K., Sulkowsky M.S. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N. Engl. J. Med. 2009, 361:580-593. IDEAL Study Team.
14. Reimer J., Haasen C. Need-adapted HCV-treatment setting for injection drug users. Lancet 2009, 373:2090-2091.
15. Reimer J., Schulte B., Castells X., Schaefer I., Polywka S., Hedrich D., Wiessing L., Haasen C., Backmund M., Krausz M. Guidelines for the treatment of hepatitis C virus infection in injection drug users: status quo in the European Union countries. Clin. Infect. Dis. 2005, 40(Suppl. 5):S373-S378.
16. Robins L.N., Wing J., Wittchen H.U., Helzer J.E., Babor T.F., Burke J., Farmer A., Jablenski A., Pickens R., Regier D.A., Sartorius N., Towle L.H. The Composite International Diagnostic Interview. An epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures. Arch. Gen. Psychiatry 1988, 45:1069-1077.
17. Roy E., Alary M., Morissette C., Leclerc P., Boudreau J.F., Parent R., Rochefort J., Claessens C. High hepatitis C virus prevalence and incidence among Canadian intravenous drug users. Int. J. STD AIDS 2007, 18:23-27. SurvUDI Working Group.
18. Schackman B.R., Teixeira P.A., Beeder A.B. Offers of hepatitis C care do not lead to treatment. J. Urban Health 2007, 84:455-458.
19. Shebab T.M., Orrego M., Chunduri R., Look A.S. Identification and management of hepatitis C in patients in primary care clinics. Am. J. Gastroenterol. 2003, 98:639-644.
20. Stohler R., Dürsteler-MacFarland K.M., Gramespacher C., Petitjean S., Battegay R., Ladewig D. A comparison of heroin chasers with heroin injectors in Switzerland. Eur. Addict. Res. 2000, 6:154-159.
21. Wittchen H.U., Semler G. Composite International Diagnostic Interview (CIDI). Deutsche Bearbeitung 1990, Beltz, Weinheim.
22. Zeuzem S. Standard therapy of acute and chronic hepatitis C. Z. Gastroenterol. 2004, 43:714-719. (in German).